Applicaiton Required

ISPY1

ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting pathologic complete response (pCR) and recurrence-free survival (RFS).Participant Eligibility and Enrollment: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.

Acknowledgements This shared data set was provided by David Newitt, PhD and Nola Hylton, PhD from the Breast Imaging Research Program at UCSF, in collaboration with ACRIN, CALGB, the I-SPY TRIAL, and TCIA. Many thanks are due to The ACRIN 6657 trial team, The I-SPY 1 TRIAL team, and all the patients participating in these studies

Funding sources include NIH grants to UCSF (R01 CA132870 and U01 CA151235), ACRIN (UO1 CA079778 and UO1 CA080098), and CALGB (UO1 CA31964 and UO1 CA33601).

データとリソース

このデータセットにはデータがありません

追加情報

フィールド
最終更新 12月 3, 2019, 14:29 (CST)
作成日 2月 14, 2019, 10:19 (CST)

推薦資料集:


  • 經濟部中小企業處_地方產業發展基金會計報告

    Payment instrument Free
    Update frequency Irregular
    地方產業發展基金收支餘絀表及平衡表
  • 南部科學園區土地規劃資料集

    Payment instrument Free
    Update frequency Irregular
    1.總面積:經都市計畫及非都市計畫審議通過之土地總面積。 總面積=工業區面積 + 住宅區面積 + 其他用地面積 2.工業區面積:經都市計畫及非都市計畫編為事業專用區之面積。 3.住宅區面積:經都市計畫及非都市計畫編為住宅區之面積。 4.其他用地面積:總面積扣除工業區及住宅區面積。
  • 就業服務據點

    Payment instrument Free
    Update frequency Irregular
    本資料集提供就業服務據點(本資料為固定資料,如有變動才有更新,非隨年度更新)
  • 107年10月花蓮縣各項稅捐實徵淨額與預算數及上年同期比較-累計數

    Payment instrument Free
    Update frequency Irregular
    花蓮縣各項稅捐實徵淨額與預算數及上年同期比較-累計數
  • 私募有價證券無實體登錄資料查詢:普通股

    Payment instrument Free
    Update frequency Irregular
    私募有價證券無實體登錄資料查詢:普通股(臺灣集中保管結算所)